Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $104 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $104 price target.
June 22, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Axsome Therapeutics and maintained a $104 price target.
The reiteration of an Overweight rating and maintenance of a $104 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Axsome Therapeutics. This news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100